Tirzepatide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Tirzepatide is administered via subcutaneous injection at 5-15 mg weekly once weekly. Subcutaneous injections into the abdominal fat or thigh are most common. Proper reconstitution with bacteriostatic water is required first.
How Do You Inject Tirzepatide?
Tirzepatide is administered via subcutaneous injection. For most researchers, subcutaneous injection is the standard approach — it's simple, relatively painless, and effective for Dual GIP/GLP-1 receptor agonist compounds.
This guide covers injection technique, site selection, needle choices, and common mistakes.
How Do You Prepare for a Tirzepatide Injection?
Step 1: Wash your hands thoroughly.
Step 2: Clean the top of the Tirzepatide vial and BAC water vial with alcohol swabs. If not yet reconstituted, see our Tirzepatide reconstitution guide.
Step 3: Draw your dose (5-15 mg weekly) into an insulin syringe. Use our calculator for exact units.
Step 4: Clean the injection site with an alcohol swab and let it dry.
What Is the Correct Injection Technique?
Subcutaneous (most common): Pinch a fold of skin — typically abdominal fat 2+ inches from the navel, or the thigh. Insert the needle at a 45-degree angle. Push the plunger slowly and steadily. Hold for 5 seconds, then withdraw.
Intramuscular (less common for Tirzepatide): Insert the needle at 90 degrees into the muscle (deltoid or vastus lateralis). This route provides faster absorption but isn't necessary for most peptide protocols.
Rotate injection sites to prevent lipodystrophy (fat tissue changes from repeated injections in the same spot).
What Size Needle Should You Use?
For subcutaneous Tirzepatide injections, 29-31 gauge insulin needles (½ inch or 8mm) are standard. These are thin enough to be nearly painless while long enough for proper subcutaneous delivery.
Use a fresh needle for every injection. Never reuse or share needles.
Calculate Your Tirzepatide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Tirzepatide.
Open Calculator →What Are Common Injection Side Effects?
Mild redness, swelling, or itching at the injection site is normal and typically resolves within hours. Small bruises can occur, especially if you hit a capillary.
If you experience persistent pain, swelling, warmth, or redness lasting more than 24 hours, discontinue and consult a healthcare provider — these may indicate infection.
Bottom Line on Tirzepatide Injection
Tirzepatide is administered via subcutaneous injection at 5-15 mg weekly once weekly. Subcutaneous injection with a 29-31 gauge insulin needle into abdominal fat is the standard technique. Rotate sites and use a fresh needle every time.
Complete Guide
Tirzepatide : Benefits, Dosage, Side Effects & Research
Related Reading
- Tirzepatide Dosage Guide
- Tirzepatide Benefits
- Tirzepatide Side Effects
- Tirzepatide Stacking Guide
- Tirzepatide Cycle Guide
- Tirzepatide Research
Research-Grade Sourcing
If you're going to research Tirzepatide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide (Tirzepatide (GIP/GLP-1 dual receptor agonist)) is a Dual GIP/GLP-1 receptor agonist. Engineered peptide from native GIP sequence with dual affinity for GIP and GLP-1 receptors; developed by Eli Lilly. It is researched for superior weight loss vs GLP-1 monotherapy, glycemic control, cardiovascular improvement, sleep apnea improvement.
What is the recommended Tirzepatide dosage?
Common dosages: 5-15 mg weekly administered once weekly via subcutaneous injection. Cycle length: ongoing with titration over 16 weeks. Half-life: 5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Tirzepatide?
GI effects most common — nausea, vomiting, diarrhea/constipation (20-50%, decreasing after 4-8 weeks). Rare pancreatitis and gallbladder events. Retinopathy worsening possible in severe diabetes.
Is Tirzepatide safe?
Tirzepatide has shown a preliminary safety profile in research. FDA-approved (Zepbound for weight, Mounjaro for diabetes). Prescription medication. All research should follow appropriate safety protocols.